ISRCTN89754756已完成未知
Stage 3 Pilot Study: a decision tool to improve the management of urinary incontinence in women in the community
niversity of York (UK)0 个研究点目标入组 150 人开始时间: 2011年3月18日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthcare professionals: Any healthcare professional who works in a community/primary care setting whose role involves assessment and management of urinary incontinence in women in the community. Health care professionals will be working within two primary care trusts where NHS permissions will be sought for the study to proceed
- •2. Patients: Women who are over 18 years of age, not pregnant and have symptoms of urinary incontinence are eligible to be invited into the study.; Target Gender: Male & Female ; Lower Age Limit 18 no age limit or unit specified
排除标准
- •1. Health care professionals who were involved in the intial development of the decision tool
- •2. Patients who are under 18 years of age
- •3. Patients who are pregnant
- •4. Patients who are unable to give informed consent
研究者
相似试验
进行中（未招募）
1 期
First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole.Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis.MedDRA version: 14.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-005409-38-ESFundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)56
进行中（未招募）
1 期
Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCERPacientes con cáncer de próstata metastásico sin experiencia de quimioterapia y con elevación documentada del antígeno prostático específico (PSA) o enfermedad progresiva (EP) documentada después de tratamiento hormonal.Chemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 12.0Level: PTClassification code 10036909Term: Prostate cancer metastaticEUCTR2008-007969-23-ESCelgene Corporation1,015
进行中（未招募）
1 期
Ensayo pivotal de fase III para determinar la eficacia y la seguridad del comprimido bucodispersable de vardenafilo comparado con placebo en el tratamiento de hombres con disfunción eréctil (DE) – ensayo multicéntrico, aleatorizado, doble ciego y de dosis fija – POTENT I Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, raNdomized multi-center Trial - POTENT I - POTENT IEUCTR2008-000536-40-ESBayer HealthCare AG
进行中（未招募）
3 期
A phase 3 study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndromeFamilial Chylomicronemia SyndromeGenetic DiseasesISRCTN12904794Arrowhead Pharmaceuticals, Inc.76
已完成
3 期
A Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in subjects with castrate-resistant prostate cancer.prostate cancer that can't be treated surgically1003859710036958NL-OMON43687Celgene Corporation136